This study is in progress, not accepting new patients
A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial
Summary
- Eligibility
- for people ages 18-80 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Imbria Pharmaceuticals, Inc.
- ID
- NCT04826185
- Phase
- Phase 2 Cardiomyopathy Research Study
- Study Type
- Interventional
- Participants
- About 67 people participating
- Last Updated